Services on Demand
Journal
Article
Indicators
Cited by SciELO
Access statistics
Related links
Cited by Google
Similars in SciELO
Similars in Google
Share
Revista Colombiana de Cardiología
Print version ISSN 0120-5633
Abstract
MACHADO-ALBA, Jorge E.; GARCIA-BETANCUR, Santiago; VILLEGAS-CARDONA, Federico and MEDINA-MORALES, Diego Alejandro. Prescription patterns of new oral blood thinning drugs and their economic impact in Colombia. Rev. Colomb. Cardiol. [online]. 2016, vol.23, n.4, pp.277-285. ISSN 0120-5633. https://doi.org/10.1016/j.rccar.2015.08.005.
Introduction: For decades, vitamin K antagonists were the drugs available for management of patients requiring anticoagulation therapy. The so-called new oral blood thinners, with an apparently better safety profile, have been approved for some cases; however, Colombia still lacks the information on prescription patterns for these drugs. Objetive: To determine prescription patterns of new oral blood-thinning drugs and the variables associated to their intake in a group of patients affiliated to the Colombian General Health and Social Security System (SGSSS) during 2014. Methods: Cross-sectional observational study. Patients taking dabigatran, rivaroxaban and apixaban during the February-April 2014 quarter were selected from the database of 6.5 SGSSS affiliated members. Sociodemographic, pharmacological, co-medication (comorbidities) and economic variables were assessed. Student's t test, chi-square test and logistic regression models were used. Results: A total of 1,310 patients were administered new oral blood thinners, with a male predominance (57.2%), in single-drug therapy (88%), and an association with antiplatelet drugs was present in 10.5% of the cases. The most commonly prescribed medication was rivaroxaban (52.9%). The cost per 1,000 people/day of dabigatran COL $ 334.6, of rivaroxaban COL $ 930.7 and apixaban COL $ 32.6. 49.1% of the patients had a diagnosis of atrial fibrillation. Conclusions: Rivaroxaban was the medication with the greater cost. Based on these patterns it can be determines that the new oral blood-thinning drugs are being used mainly as a single-drug therapy. More studies assessing the efficacy and safety profile in Colombian population need to be conducted.
Keywords : Blood-thinning drugs; Dabigatran; Rivaroxaban; Aprixaban; Pharmacoepidemiology; Primary care; Colombia.